Julie Vose, MD, MBA, on DLBCL and FL: Expert Commentary on Two Studies
2017 ASCO Annual Meeting
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discusses two hematologic abstracts: results from the OPTIMAL>60 study on radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly patients with diffuse large B-cell lymphoma; and an analysis of autologous vs matched sibling donor or matched unrelated donor allogeneic hematopoietic cell transplantation in follicular lymphoma patients with early chemoimmunotherapy failure. (Abstracts 7506, 7508)
Nicholas D. James, MBBS, PhD, of Queen Elizabeth Hospital, discusses study findings on adding abiraterone for men with high-risk prostate cancer starting long-term androgen-depriva...
Dean F. Bajorin, MD, of Memorial Sloan Kettering Cancer Center, and Peter H. O’Donnell, MD, of The University of Chicago Medical Center, discuss their study findin...
Daniel Heng, MD, MPH, of the Tom Baker Cancer Centre and the University of Calgary, and Sumanta K. Pal, MD, of the City of Hope, discuss key findings presented at ...
Ann-Lii Cheng, MD, PhD, of the National Taiwan University Hospital, discusses phase III study findings on lenvatinib vs sorafenib in first-line treatment of patients with unresecta...
Peter Hoskin, MD, of Mount Vernon Cancer Centre, discusses study findings on single-dose radiotherapy compared with multifraction radiotherapy in patients with metastatic spinal ca...
